- Poster presentation
- Open Access
Ferumoxytol across the age spectrum: a single center experience of safety
© Nguyen et al. 2016
- Published: 27 January 2016
- Chronic Kidney Disease
- Contrast Agent
- Congenital Heart Disease
- Pulse Oximetry
- Single Center Experience
Ferumoxytol is used for parenteral iron therapy in patients with chronic kidney disease (CKD). Because of its uniquely powerful properties as an intravascular MR contrast agent, there is growing interest in the safety of ferumoxytol as a possible alternative to gadolinium-based contrast agents in patients with CKD and in patients with congenital heart disease. We reviewed the frequency, type and severity of adverse reactions to ferumoxytol as an MRI contrast agent over a broad spectrum of ages and indications in a single center study.
Following informed consent and with approval from our IRB, we performed ferumoxytol enhanced MRA (FEMRA) for the assessment of pathologic arterial and /or venous anatomy in 165 patients (age 36 ± 28 years, range 3 days to 94 years, 38% female). Both bolus and slow infusions were given (total dose of 4 mg /kg, 166 injections). Sixty-five patients were examined under general anesthesia; three had pacemakers and six were pregnant. First pass and steady state FEMRA were performed in 119 patients and 46 patients had only steady state imaging. Continuous monitoring of ECG, pulse oximetry, and non-invasive blood pressure was performed in all patients and the electronic medical records were reviewed to assess for follow up events.
In all cases, patients remained stable throughout the FEMRA studies and there were no serious adverse events. In two patients, systolic blood pressure (SBP) transiently decreased by 10-15 mmHg and in 22 patients SBP increased by 10-15 mmHg. In eight patients with congenital heart disease, blood oxygenation decreased by 1-5% during the MRI study. Three patients developed nausea following injection of ferumoxytol but in all cases the studies were completed successfully.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.